Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Jump to

    • Buy Pfizer India; target of Rs 4800: Anand Rathi

    • Hold Pfizer; target of Rs 4505: ICICI Direct

    • Hold Pfizer; target of Rs 4480: ICICI Direct

    • Buy Pfizer; target of Rs 4810: ICICI Direct

    • Hold Pfizer: target of Rs 6690: ICICI Direct

    • Buy Pfizer India; target of Rs 5655: Anand Rathi

    • Buy Pfizer; target of Rs 5890: ICICI Direct

    • Buy Pfizer; target of Rs 4740: ICICI Direct

    • Buy Pfizer; target of Rs 4705: ICICI Securities

    • Buy Pfizer; target of Rs 3100: Centrum

    • Buy Pfizer; target of Rs 3000: ICICI Direct

    • Buy Pfizer; target of Rs 2300: Centrum

    • Hold Pfizer; target of Rs 2010: Centrum

    • Buy Pfizer; target of Rs 2425: ICICIdirect

    • Buy Pfizer; target of Rs 1270: Firstcall Research

    • Buy Pfizer; target Rs 1720: Firstcall Research

    • Buy Pfizer; target Rs 1107: Firstcall Research

      Brokerage house Firstcall Research is bullish on Pfizer and has recommended buy rating on the stock with a target price of Rs 1107 in its August 28, 2013 research report.

    • Buy UltraTech, Madras Cements, Pfizer, Mcleod: AnandRathi

      AnandRathi Securities has recommended to buy UltraTech Cement, Pfizer, Madras Cements and Mcleod Russel India with a target price of Rs 2100, Rs 215, Rs 1232 and Rs 400 respectively, in its research report dated July 30, 2013.

    • Buy Pfizer; target of Rs 1300: Firstcall Research

      Firstcall Research is bullish on Pfizer and has recommended buy rating on the stock with a target of Rs 1300 in its December 07, 2012 research report.

    • Accumulate Pfizer; target of Rs 1265: Emkay

      Emkay Global Financial Services is bullish on Pfizer and has recommended accumulate rating on the stock with a target of Rs 1265 in its August 16, 2012 research report.

    • Buy Pfizer; target of Rs 1339: Firstcall Research

      Firstcall Research is bullish on Pfizer and has recommended buy rating on the stock with a target of Rs 1339 in its December 7, 2011 research report.

    • Accumulate Pfizer; target of Rs 1417: Emkay

      Emkay Global Financial Services is bullish on Pfizer and has recommended accumulate rating on the stock with a target of Rs 1417 in its May 4, 2011 research report.

    • Accumulate Pfizer; target of Rs 1193: Emkay

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347